# Optofluidics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/optofluidics

- Industry: Biotechnology
- Headquarters: Burlingame, US
- Website: www.halolabs.com
- Total disclosed funding: $15M
- Latest round: Series C (Jun 30, 2022)
- Investors on record: 5

## About

Optofluidics, Inc. specializes in advanced particle analysis technologies that facilitate biotherapeutic development through innovative particle analyzers.Founded in 2011 in Burlingame, US, Optofluidics, Inc. focuses on developing technologies for biotherapeutic applications. The company successfully secured funding through a Series C round led by Agilent Technologies Inc. in October 2018, raising USD 7.00 mn, which contributed to a total amount raised of USD 7.00 mn. Currently, the company's valuation stands at USD 56.33 mn. Christopher Fox is the founder, and Rick Gordon serves as the CEO.Optofluidics, Inc. offers the Aura family of particle analyzers, which includes the Aura+, Aura PTx, Aura GT, and Aura CL systems. These systems utilize advanced technologies such as Backgrounded Membrane Imaging (BMI) and Fluorescence Membrane Microscopy (FMM) for high-throughput particle characterization. Their products cater to biopharmaceutical companies and research institutions, ensuring compliance with standards like USP 788, while enhancing the efficiency and accuracy of particle analysis in drug development.In 2019, Optofluidics, Inc. reported revenue of USD 28.20 mn and an EBITDA of USD -23.80 mn. The company generates revenue primarily through direct sales of its particle analyzers and associated services, including software and training programs, which are designed to enhance laboratory workflows in drug development.Optofluidics, Inc. plans to leverage its recent funding from the Series C round to develop new products and expand its presence in international markets. The company is focused on enhancing its particle analysis technologies and aims to introduce new models by the end of the next fiscal year. Additionally, the company is considering expansion into European and Asian markets to broaden its client base in the biopharmaceutical sector.

## Funding rounds

- Series C, Jun 30, 2022, $7M — Research Corporation Technologies, Agilent Technologies Inc., BioAdvance, BroadOak Capital Partners
- Series B, Mar 31, 2020, $6.7M — Research Corporation Technologies, BioAdvance, BroadOak Capital Partners
- Seed, May 6, 2015, $0.1M — Ben Franklin Technology Partners
- Seed, Jun 13, 2014, $0.3M — BioAdvance
- Seed, Jan 30, 2014, $0.1M — Ben Franklin Technology Partners
- Seed, Jun 26, 2012, $0.8M — BioAdvance

## Investors

- BioAdvance (https://capitalatlas.ai/funds/bioadvance) — Seed, Series B, Series C
- Ben Franklin Technology Partners (https://capitalatlas.ai/funds/ben-franklin-technology-partners) — Seed
- Research Corporation Technologies (https://capitalatlas.ai/funds/research-corporation-technologies) — Series B, Series C
- BroadOak Capital Partners (https://capitalatlas.ai/funds/broadoak-capital-partners) — Series B, Series C
- Agilent Technologies Inc. — Series C